Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LumiraDx Limited LMDX

LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care.


Recent & Breaking News (NDAQ:LMDX)

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

GlobeNewswire 13 days ago

LumiraDx Reports Third Quarter 2022 Results

GlobeNewswire November 9, 2022

LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9

GlobeNewswire November 2, 2022

LumiraDx Reports Second Quarter 2022 Results

GlobeNewswire August 18, 2022

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

GlobeNewswire August 11, 2022

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

PR Newswire July 21, 2022

LumiraDx Announces Proposed Public Offering of Common Shares

PR Newswire July 19, 2022

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

PR Newswire June 9, 2022

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete

PR Newswire June 8, 2022

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

PR Newswire June 2, 2022

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

PR Newswire May 26, 2022

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

PR Newswire May 20, 2022

LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

PR Newswire May 19, 2022

LumiraDx Reports First Quarter 2022 Results

PR Newswire May 11, 2022

LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11

PR Newswire April 29, 2022

LumiraDx Reports Fourth Quarter and Full Year 2021 Results

PR Newswire March 10, 2022

LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10

PR Newswire March 3, 2022

LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering

PR Newswire March 1, 2022

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

PR Newswire January 14, 2022

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

PR Newswire January 11, 2022